Specifically, the court found that the sponsor ???currently faces no competition in the PrEP market, because no other drug has been approved by the FDA for such use, and no such drugs are in advanced clinical trials.???5 Similarly, the court found that the FDA failed to adduce specific, admissible evidence that future competition will exist between the sponsor and other companies working to develo